EVFM News and Press, Evofem Biosciences Inc. From 05/20/22

Evofem Biosciences (EVFM) -43% on planned public offering. Ross Stores (ROST) -23% on Q1 results. Bright Green (BGXX) -12%. NeuroMetrix (NURO) -10%. Burlington Stores (BURL) -10%. Novan, Inc. (NOVN) -8%. Upstart Holdings (UPST) -7% Saxena White P.A. files new securiti...

Evofem Biosciences (NASDAQ:EVFM) stock slumped ~ 46% premarket May 20 after the company said on Thursday that it was planning to sell shares and warrants in a public offering. EVFM -45.59% to $0.60 premarket May 20. The San Diego-based biopharma company plans to ...

Evofem Biosciences (NASDAQ:EVFM) on Thursday announced an underwritten public offering of shares (or pre-funded warrants to purchase stock) and warrants. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms. Net proceeds will be used for c...

Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi® PR Newswire SAN DIEGO , May 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq:&...

Announcing new data from a late-stage study, the commercial-stage biopharma company Evofem Biosciences (NASDAQ:EVFM) said on Friday that the women who used its Phexxi birth control gel experienced fewer urinary tract infections (UTIs) compared to the general population. A post-hoc analysis of...

Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial PR Newswire 5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General Population ...

Evofem Biosciences (NASDAQ:EVFM) trades 14.3% down premarket after it announced that the board and shareholders approved a 1-for-15 reverse stock split of its stock, effective today. The stock will continue to trade under the symbol, "EVFM". The reverse stock split is inte...

Evofem Biosciences Announces 1-for-15 Reverse Stock Split PR Newswire SAN DIEGO , May 5, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. , (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 ...

Evofem Biosciences, Inc. (EVFM) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier - Chief Executive Officer, President and Executive Director Jay File - Chief Financial Officer Conference Call Particip...

Evofem Biosciences press release (NASDAQ:EVFM): Q1 Revenue of $4.3M (+287.4% Y/Y). At March 31, 2022, the Company had $2.8 million in unrestricted cash and $4.2 million in restricted cash, as compared to $7.7 million of unrestricted cash and $5.1 million of restricted cash at Decemb...